Group B Streptococcus Infection Market Outline: (Disease outline would assist in understanding disease progress, accordingly target appropriate segment for futuristic development)
The 9MMGroup B Streptococcus Infection Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.
Group B Streptococcus (GBS) bacteria most commonly live in people’s gastrointestinal and genital tracts. Typically, they do not cause any harm to human body, but sometime it invades in the body and causes various types of complications, which generally referred as infections. Their spectrum of infections is quite wide, may infect various body sites such as it may cause Bacteremia (bloodstream infection) and sepsis, Bone and joint infections, Pneumonia (lung infection), Skin and soft-tissue infections, Meningitis (infection of the tissue covering the brain and spinal cord) among others.
Long-term infections especially in babies and women could cause severe complications. Group B Streptococcus (GBS) is currently considered as prominent cause of infant morbidity and mortality
It is estimated that more than 10 million deaths will be caused by antimicrobial resistance (AMR) by 2050. Even now global health care bodies have raised serious concerns regarding antimicrobial resistance (AMR) across major markets.
Patients on antibiotics for a longer period, are more susceptible to get bacterial infections. Lack of substantial progress in the developments of novel antibiotics limiting treatment options. Thus, majority of the patients rely on already available antibiotics leading to large number of AMR case around the world. According to World bank estimates, AMR could result in approximately USD 1 trillion an additional healthcare cost burden by 2050, and US$ 1 trillion to US$ 3.4 trillion GDP losses per year by 2030
Looking at above statistics, development of novel therapeutics option is imperative to provide curable treatment options. Studies meta-analysis demonstrated GBS infection causes a considerable burden of sepsis and meningitis in newborns.
Group B Streptococcus Infection Burden Analysis: (Result shown here is reflecting from meta-analysis, and CSP Analytics Solutions Analysis)
This section explored the epidemiology associated with Group B Streptococcus Infection
In the global context, higher prevalence registered in South East Asian countries
In the year, 2022 nearly 21.76 million pregnant women across the globe were colonised with GBS. Nearly 5 to 20% of non-pregnant women with GBS infection have urinary tract infections, and mostly such infections occur in elderly adults
Around 4.1% to 5.7% of babies who develop GBS disease are susceptible to die.
There are 10-15 cases in every 100,000 non-pregnant adults each year.
There are around 25-30 cases in every 100,000 adults 65 years or older each year.
Total infants’ infections cases in XX million (9MM)
Total pregnant women infections cases in XX million (9MM)
Total elderly infections cases in XX million (9MM)
XX million cases receiving treatment
Number of cases prevalent, annually diagnosed cases
Treatment Landscape:
Treatment of Group B Streptococcus Infections requires holistic framework to address diverse set of patients accompanied with various therapeutic conditions (Co-morbidities). Collaboration among various specialties imperative to devise tailoring treatment plan. Efforts to promote antimicrobial stewardship and advocacy at patient and physician level is crucial approaches to mitigate the risk of antibiotic resistance.
Various treatment approaches involve while treating Group B Streptococcus Infection patients such as Antibiotic Therapy either asprophylactic and for treatment
Report evaluated players involves in the developments of vaccine technological platforms (Ex. Glycoconjugate vaccine)and their expected launches. Since there is no vaccine is licensed for the prevention of GBS.
Patients with different modalities, requires tailoring treatment options, since treatment accompanied with various challenges while treating pregnant women, neonatal and geriatric patients.
Report explored, treatment strategies for different set of patients. What are the approaches embraced by physicians, while treating patients with co-morbidities and without co-morbidities
Group B Streptococcus Infection market is struggling to get an effective treatment. High spectrum antibiotics is currently the mainstay of therapy for patients
Recent clinical guidelines enable the streamlining the treatment approaches
Report, investigated patient segment targeted by each therapy type:
Report has examined the how many and what type of cases refer to which type of therapy based on experts’ opinion analysis.
Report also examined Approaches for Management
Prophylaxis (Preventive Care)
Treatment
Drug
Targeted Patient Segment
Antibiotics
Prophylaxis (Prevention)
Treatment
XX
Vaccines
XX
Targeted Respondents Covered
Infectious Disease Specialists
XX
General Physician
XX
Orthopedic Surgeons
XX
Upcoming Therapy Assessment (Pipeline Analysis)
Report also provided promising therapy assessment including drugs, existing therapies, and upcoming therapy
Novel drug target assessment. For instance, development of vaccine-based therapy
Expected launch of key pipeline assets
Report alsoinvestigated novel therapy development (Ex. Vaccine), their potential health impact and cost-effectiveness, which has not been assessed globally.
Experts Opinion on the matter of accepting novel treatment options
Promising molecules advantages offer over existing therapy
Impact assessment of pipeline assets
Drug analogue analysis
Expected annual cost of therapy
Recent Advancements:
Pfizer’s Group B Streptococcus Vaccine Candidate received FDA Breakthrough Therapy Designation to Prevent Infection in Infants Via Immunization of Pregnant Women
Trial activities supported by funding organization, such as in this case grant received from the Bill & Melinda Gates Foundation, which endorsed the ongoing Phase 2 clinical trial of GBS6.
Market Segmentation Analysis by:
By Cases Type
Early-Onset Disease
Late-Onset Disease
By Infection Type
Maternal Colonization
Neonatal Infection
Adult Infections
By Treatment Type
Antibiotics
Prophylaxis (Prevention) Treatment
By Gender
Female
Male
By Route of Administration
Oral
Injectable
By Infections Source
Hospital-acquired Infections
Community-acquired Infections
Market Dynamics: Explored in the report
Untreated Prevalent Pool of Group B Streptococcus Infection
Huge medical unmet need
Rising Incidence and prevalence of GBS Infections
Proliferation of novel treatment options
Increasing awareness and screening programs
Continued investments in research and developmental activities by pharmaceutical companies, biotechnology firms, and academic institutions contribute to the development of innovative diagnostic tools, treatments, and vaccines for GBS infection, further driving market growth.
Market Challenges: Explored in the report
Inadequate efficacious treatment options
Surging antibiotic resistance cases
Long-term treatment consequences
Neonatal Sepsis Management: Neonatal GBS sepsis requires prompt recognition and treatment with appropriate antibiotics to prevent serious complications such as meningitis and long-term neurodevelopmental sequelae. However, distinguishing GBS sepsis from other neonatal infections can be challenging, and delays in diagnosis and treatment can significantly impact outcomes.
Treating AMR cases
Research gap
Cost of therapy
Treatment compliance and adherence
Mapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States Group B Streptococcus Infection Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
5-Europe Group B Streptococcus Infection Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China Group B Streptococcus Infection Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India Group B Streptococcus Infection Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan Group B Streptococcus Infection Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World Group B Streptococcus Infection Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Competitive Landscape (Existing and Pipeline Players):
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
